TGFB2 and gastrointestinal stromal tumor: Recombinant TGF-β2 protein treatment led to a decrease in the rate of GIST apoptosis (as portrayed in A, B), a deviation from their normal cell cycle progression (as demonstrated in Fig. 6C, D), and an elevation in their survival rate (as exemplified in Fig. 6E) upon being subjected to IM treatment.